Search Clinical Trials | Froedtert & MCW

Keyword

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

28 results for "Cancer" and "Head and Neck Cancers"

A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer

Protocol No

IIT-AWAN-NIH-DEHART

Sub Category

Head and Neck Cancers

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Protocol No

RTOG-1008

Sub Category

Head and Neck Cancers

A Topical Antiseptic Bundle for Decreasing Surgical Site Infection after Head Neck Cancer Surgery: Peri-operative Effects on the Oral Microbiome

Topical Antisepsis in Head and Neck Cancer Surgery

Protocol No

IIT-ZENGA-ANTISEPSIS

Sub Category

Head and Neck Cancers

A Phase I/II Study of TheraT^® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.

Protocol No

HOOKIPA-H-200-001

Sub Category

Gynecologic Cancers

Early Phase/Multiple Disease Site Cancers

Head and Neck Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers

Randomized Phase II/III trial of adjuvant radiation therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in pathologic high-risk Squamous Cell Cancer of the head and neck

The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.

Protocol No

RTOG-1216

Sub Category

Head and Neck Cancers

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA

This study is being done to answer the following question: Does maintenance nivolumab following definitive therapy with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (OS) (time being alive) and progression-free survival (PFS) (time being alive without cancer) for patients with your type of cancer (intermediate risk HPV positive oropharynx cancer). We are doing this study because we want to find out if this approach is better or worse than the usual approach for your HPV positive oropharynx cancer. The usual approach is defined as care most people ...

Protocol No

ECOG-EA3161

Sub Category

Head and Neck Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...

Protocol No

ALLIANCE-A151804

Sub Category

Gastrointestinal Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility

Protocol No

ADP-0000-001-SCR

Sub Category

Gynecologic Cancers

Prostate and Urologic Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Head and Neck Cancers

Gastrointestinal Cancers

Phase II Randomized Trial Of Neo-Adjuvant Chemotherapy Followed By Surgery And Post-Operative Radiation Versus Surgery And Post-Operative Radiation For Organ Preservation Of T3 And T4a Nasal And Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area

Protocol No

ECOG-EA3163

Sub Category

Head and Neck Cancers

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Cancer

SBRT +/- Pembrolizumab in Patients w/ Local-Regionally Recurrent or 2nd Primary Head and Neck Cancer

Protocol No

RTOG-3507

Sub Category

Head and Neck Cancers

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

Protocol No

AFT-25-COMET

Sub Category

Breast Cancers

A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

Protocol No

ADP-0055-001-MAGE-A4-SURPASS

Sub Category

Gastrointestinal Cancers

Skin Cancers

Thoracic Cancers

Sarcoma

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

An Exploratory Study of Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance

Endocrine therapy before surgery to assess disease response and mechanisms of resistance in tumor cells

Protocol No

IIT-CHAUDHARY-ENDOCRINE

Sub Category

Breast Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Protocol No

ACCRU-SC-1601

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Eye/Orbital Cancers

Endocrine Cancers

Breast Cancers

Brain and Spine Cancers

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Protocol No

IOVANCE-IOV-COM-202

Sub Category

Head and Neck Cancers

Thoracic Cancers

Skin Cancers

Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy

This project is being done to assess the effectiveness of adding the drug Cemiplimab to the standard neoadjuvant chemotherapy regimen in patients with estrogen receptor and/or progesterone receptor positive, HER2 negative, or triple-negative invasive breast cancer.

Protocol No

IIT-CHAUDHARY-PD1-CEMIPLIMAB

Sub Category

Breast Cancers

A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-stage, P16-positive, Non-smoking Associated Oropharyngeal Cancer

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Protocol No

NRG-HN005

Sub Category

Head and Neck Cancers

Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab In Patients With Locoregionally Recurrent Or Second Primary Squamous Cell Cancer Of The Head And Neck

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Protocol No

WINSHIP-4221-17

Sub Category

Head and Neck Cancers

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

Comparing Radiation Plus Antibody Therapy to Radiation Plus Immune Therapy in People With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Protocol No

NRG-HN004

Sub Category

Head and Neck Cancers

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Protocol No

ALLIANCE-A011202

Sub Category

Breast Cancers